New drug combo for advanced lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that has spread or returned after immunotherapy.
- You are at least 18 years old and can provide a tumor sample from before treatment.
- You have not had gemcitabine combined with immunotherapy before.
- You have stable brain metastases if treated, and no active or serious heart, lung, or bleeding problems.
- You agree to use effective contraception during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose lung cancer has spread to the tissues around the brain and spinal cord (leptomeningeal metastasis) and who have already tried a targeted therapy that stopped working. The goal is to see if this combo can control the cancer better.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
This study tests a new combination of medications to keep stage III lung cancer from coming back after initial radiation and chemotherapy. It aims to see if this approach can help people live longer without their cancer returning.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.